{"Clinical Trial ID": "NCT01740323", "Intervention": ["INTERVENTION 1:", "- Placebo", "- Placebo", "Placebo: daily placebo for 6 weeks", "INTERVENTION 2:", "- Curcumin", "500 mg twice daily", "Curcumin: 500 mg twice daily"], "Eligibility": ["Incorporation criteria:", "In this study, women with breast cancer over 18 years of age will be recruited and patients enrolled in the study will meet the standard criteria for whole breast radiation therapy.", "- Exclusion criteria:", "Subjects with a history of major psychiatric disorders, including schizophrenia or bipolar disorder, or a diagnosis of substance abuse or addiction in the past year (according to a standard psychiatric interview) will be excluded. Subjects taking medicines known to affect the immune system (e.g. glucocorticoids, methotrexate) will also be excluded. Subjects using supplements or other natural products with one week of starting drugs, excluding vitamins and calcium supplementation or at the discretion of the treating physician, will be excluded."], "Results": ["Performance measures:", "PBMC NF-kB DNA bond measured in ng/Well", "The main result to be measured will be the modification of NF-kB DNA binding (measured in peripheral blood mononuclear cells to ng/well) after six weeks of placebo or Meriva therapy. NF-kB DNA binding was associated with fatigue in breast cancer patients.", "Timeline: Baseline, 6 weeks after completion of XRT review", "Results 1:", "Title of the arm/group: Placebo", "Description of the arm/group: Placebo", "Placebo: daily placebo for 6 weeks", "Total number of participants analysed: 13", "Average (standard deviation)", "Unit of measure: ng/well Reference: 9.01 (14.70)", "6 weeks after treatment: 17.54 (9.24)", "Results 2:", "Title of the arm/group: Curcumin", "Description of the arm/group: 500 mg BID", "Curcumin: 500 mg twice daily", "Total number of participants analysed: 15", "Average (standard deviation)", "Unit of measure: ng/well Reference: 9.56 (5.63)", "Six weeks after treatment: 16.04 (16.13)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/15 (0.00 per cent)", "Thoracic pain *0/15 (0.00 %)", "Car accident *0/15 (0.00 per cent)", "Adverse Events 2:", "Total: 2/15 (13.33 per cent)", "*1/15 (6.67%)", "*1/15 (6.67 per cent)"]}